Lipoxins: Novel anti-inflammatory therapeutics?

Current Opinion in Investigational Drugs

Volumn 1, Issue 3, 2000, Pages 380-385

  Godson, C ^a   Brady, H R ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Aspirin triggered lipoxins; Inflammation; Leukocyte trafficking; Lipoxins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; LIPOPROTEIN RECEPTOR; LIPOXIN;

ANTIINFLAMMATORY ACTIVITY; CELL COMMUNICATION; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG POTENTIATION; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; NONHUMAN; REVIEW;

ANIMALS; EICOSANOIDS; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES; SIGNAL TRANSDUCTION;

EID: 0033693332     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Lipoxin biosynthesis and its impact in inflammatory and vascular events
2. Lipoxins and novel aspirin-triggered 15-epi-lipoxins [ATL]: A jungle of cell-cell interactions or a therapeutic opportunity?
3. 4 analogues inhibit leukocyte recruitment to porphoryomas gingivalis: A role for cyclooxygenase-2 and lipoxins in periodontal disease
4. Leukocyte adhesion promotes biosynthesis of lipoxygenase products by transcellular routes
5. Lipoxin generation by permeabilised human platelets
6. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte-macrophage colony-stimulating factor-primed PMNs
7. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes
8. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserved function in experimental glomerulonephritis
9. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions
10. Local and systemic delivery of a stable-aspirin-triggered lipoxin prevents neutrophil recruitment in vivo
11. Aspirin tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics
12. 4 analogs with increased biologic activity
13. 4 metabolic inactivation
14. 4 stable analogues that block transmigration and adhesion of human neutrophils
15. 4 stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors
16. 4 receptor
17. Cutting Edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages
18. Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis
19. Regulation of leukocyte trafficking by lipoxins
20. 4 inhibit leukotriene stimulated interactions of human PMNs and endothelial cells
21. 4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis
22. Leukotrienes stimulate neutrophils adhesion to mesangial cells: Modulation with lipoxins
23. 4 stable analogues are demonstrable in human whole blood: Modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions
24. 4 receptor that is regulated by interleukin[IL]-13 and interferon-γ and inhibits tumor necrosis factor α-induced IL-8 release
25. 4 analogues
26. 4 inhibit tumor necrosis alpha-initiated neutrophil responses and trafficking: Regulators of a cytokine-chemokine axis
27. 4 inhibits IL-1β-induced IL-6, IL-8 and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases
28. Lipoxins stimulate MMP-2 production in rat bone marrow-derived macrophages
29. Acute passive antiglomerular basement membrane nephritis in P-selectin deficient mice
30. 4 in human renal mesangial cells
31. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin triggered lipoxins in reperfusion
32. 4 in acute renal ischemic-reperfusion injury
33. 4-Me, a stable synthetic analogue of lipoxin A4 is protective in experimental renal ischemia reperfusion injury
34. 4 block allergen induced eosinophil trafficking
35. Recognition of apoptotic cells by phagocytes
36. Phagocyte recognition of cells undergoing apoptosis
37. Phagocytic docking without shocking
38. Human glomerular mesangial cell phagocytosis apoptotic neutrophils: Mediation by a novel CD36-independent vitronectin receptor/thrombospondin recognition mechanism that is uncoupled from chemokine secretion
39. 2 and PAF
40. 4 promote macrophage phagocytosis of apoptotic neutrophils
41. 4 and cytokine-stimulated phagocytosis of apoptotic neutrophils by bone marrow derived macrophages: Evidence for distinct regulatory pathways that may contribute to the resolution phase of inflammation
42. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes
43. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis
44. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognise and remove apoptotic cells
45. A receptor for phosphatidylserine specific clearance of apoptotic cells
46. 3]
47. 4 receptor
48. Polyisoprenyl phosphates in intracellular signalling
49. 4
50. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast
51. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein coupled receptor FPRL-1/LXA4R
52. T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein coupled formyl peptide receptors
53. 4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation
54. A seven transmembrane, G-protein coupled receptor, FPRL1 mediates the chemotactic activity of serum amyloid A for human phagocytic cells
55. Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines
56. Regulation of macrophage phagocytosis of apoptotic cells by cAMP
57. 4 in rat glomerular mesangial cells: Evidence for competition at a common receptor
58. 4 and other lipoxygenase-derived eicosanoids on tissue factor expression
59. Characterization of the human cysteinyl leukotriene CysLT1 receptor
60. Ligand independent activation of platelet-derived growth factor receptor is a necessary intermediate in lysophosphatidic acid stimulated mitogen activity in L cells
61. Regulation of tyrosine kinase cascades by G-protein coupled receptors
62. Lipoxin A: A new class of ligand for the Ah receptor
63. 4 pathway to inflammation control
64. Lipoxin recognition sites. Specific binding of labeled LXA4 with human neutrophils